{blacktriangledown}Febuxostat for gout.
Summary of "{blacktriangledown}Febuxostat for gout."
Around 1.4% of the UK population have gout, the prevalence of which increases with age to around 3% in women and 7% in men aged over 75 years.1-3 Acute gout is intensely painful and can reduce patients' quality of life.2(,)3 It occurs when the serum uric acid concentration (SUA) rises (hyperuricaemia) and persists above the solubility threshold of monosodium urate (400mumol/L [6.8mg/dL]), leading to urate crystal formation that causes arthritis, gouty tophi (nodules) in subcutaneous tissues and renal calculi.3-5 The mainstay of treatment for chronic gout is allopurinol, which inhibits xanthine oxidase (an enzyme involved in the production of uric acid in the body). However, this drug has to be stopped in a minority of patients due to rashes or hypersensitivity.6 black triangle downFebuxostat (Adenuric - Menarini/Ipsen), another xanthine oxidase inhibitor, is a newly licensed treatment for chronic hyperuricaemia in conditions where urate deposition has occurred.7 Here we consider its place for patients with gout.
Affiliation
Journal Details
This article was published in the following journal.
Name: Drug and therapeutics bulletin
ISSN: 0012-6543
Pages: 78-82
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20631196
- DOI: http://dx.doi.org/10.1136/dtb.2010.02.0017
Medical and Biotech [MESH] Definitions
Gout Suppressants
Agents that increase uric acid excretion by the kidney (URICOSURIC AGENTS), decrease uric acid production (antihyperuricemics), or alleviate the pain and inflammation of acute attacks of gout.
Benzbromarone
Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.
Apazone
An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.
Uricosuric Agents
Gout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.
Sulfinpyrazone
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
PubMed Articles
African American patients with gout: Efficacy and safety of febuxostat vs allopurinol.
ABSTRACT: BACKGROUND: African Americans are twice as likely as Caucasians to develop gout, but they are less likely to be treated with urate-lowering therapy (ULT). Furthermore, African Americans typ...
Gout therapeutics: new drugs for an old disease.
The approval of febuxostat, a non-purine-analogue inhibitor of xanthine oxidase, by the European Medicines Agency and the US Food and Drug Administration heralds a new era in the treatment of gout. Th...
Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique.
Febuxostat is used in the treatment of hyperuricemia and gout. Several impurities were detected in Febuxostat drug substance. Impurities were identified with the help of LC-MS/MS and were characterize...
Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial.
ABSTRACT: There is a disproportionate burden of gout in African-Americans in the U.S. due to a higher disease prevalence and lower likelihood of receiving urate-lowering therapy (ULT), compared to Cau...
Managing Gout in the Primary Care Setting: What You and Your Patients Need to Know.
The US prevalence of gout, a rapidly progressive inflammatory arthritic condition linked to serum uric acid levels, has grown in recent years, in part due to the increasing prevalence and incidence of...
Clinical Trials
Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
The purpose of this study is to determine the efficacy of febuxostat in reducing serum urate levels in subjects with gout.
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
The purpose of this study is to determine the long-term safety of febuxostat compared to allopurinol in reducing serum urate levels in subjects with gout.
Long-Term Safety of Febuxostat in Subjects With Gout.
The purpose of this study is to evaluate the long-term safety of febuxostat in maintaining serum urate levels within clinically acceptable levels in subjects with gout.
Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
The purpose of this study is to evaluate the safety and efficacy of febuxostat versus allopurinol in subjects with gout.
Efficacy and Safety of Oral Febuxostat in Subjects With Gout
The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.
